December 15, 2003 Comments Off on FDA Chief Eyes Path for Copycat Biotech Drugs Posted in: General Biotechnology FDA Chief Eyes Path for Copycat Biotech Drugs Food and Drug Administration Commissioner Mark McClellan said on Friday it may be justifiable for regulators to approve generic forms of biotech drugs even if they have not been through the same lengthy clinical trials required of the original drugs.
Boston’s Biotech Moment The future is moving out of dusty library stacks and into pristine laboratories on both sides of the Charles River, making this area the national leader in biotechnology. The boom is driven by a new breed of intellectual wearing a white lab coat and using science to breach the barrier between academia […]